B7-1 (CD80) ORF cDNA Lentivirus

Background

CD80, also known as B7-1, is a costimulatory cell-surface glycoprotein of the immunoglobulin superfamily expressed mainly on antigen-presenting cells such as dendritic cells, activated B cells, and macrophages. By binding the receptors CD28 and CTLA-4 on T cells, CD80 delivers a critical second signal that, together with T cell receptor engagement, governs T cell activation, proliferation, and tolerance. Engagement of CD28 promotes T cell activation, whereas binding to CTLA-4 transmits an inhibitory signal that restrains immune responses. Because the B7-CD28/CTLA-4 axis is central to immune regulation and tumor immune evasion, CD80 is widely studied in immunology, cancer immunotherapy, and checkpoint research.

Product Description & Applications

The B7-1 (CD80) ORF cDNA Lentivirus enables stable overexpression of the human or mouse CD80 open reading frame (NM_005191) in mammalian cells. A CMV or EF1a promoter drives the CD80 ORF fused to a C-terminal V5 epitope tag, with a fluorescent reporter (GFP or RFP) and an antibiotic selection marker separated by a self-cleaving peptide for independent translation from a single transcript. The optimized third-generation lentiviral vector provides high gene expression and reliable genome integration, allowing rapid establishment of stable cell lines. Applications include studying CD80 costimulatory function, T cell activation, immune checkpoint biology, and tumor immunology. Particles transduce difficult-to-transfect cells, including primary and thawed cells; cloning accuracy is confirmed by sequencing and protein expression validated by transient transfection.

About This Product

This ORF cDNA lentivirus enables stable overexpression of B7-1/CD80 (NCBI Accession: NM_005191, NM_009855) in mammalian cells via a third-generation, VSV-G pseudotyped delivery system. The ORF cDNA is fused to a C-terminal epitope tag (V5, Myc, or HA) and expressed under a strong constitutive promoter (CMV). Reporter and selection marker components (GFP, RFP; Blasticidin, Puromycin) are co-expressed via self-cleaving P2A peptides, enabling independent protein production without fusion-tag artifacts.

Ultra-purification by PEG precipitation and sucrose gradient centrifugation yields high-titer particles suitable for primary cells, suspension cultures, and stem cells. Stable polyclonal cell lines are established within 10–14 days by antibiotic selection or FACS sorting. For in vivo applications, the serum-free formulation and VSV-G envelope support direct administration or further concentration for stereotactic injection.